Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu

Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants

Research Question:
Does the drug Darbe improve cognitive function in preterm infants?

Basic Study Information

Purpose:
Study Hypothesis: Preterm infants administered weekly Darbe during the neonatal period will have improved neurocognitive outcome at 22-26 months compared to placebo

Location: University of Rochester

Study Contact Information

Study Coordinator: Carl T D'Angio, MD
Phone: (505) 272-0180
Email: rohls@salud.unm.edu

Additional Study Details

Learn More About These Conditions

More information about Premature Birth

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search